---
title: "Final Project Part 2"
author:
- "Maximilien Filion - 20598645, "
- "Aneesh Kaura - 66832304, "
- "Monica Mihailescu - 47409289 "
date: "2025-11-17"
output:
  word_document: default
  html_document: default
  pdf_document: default
---
# ============================================================================
# RNA-seq Analysis Template: Clustering and Differential Expression
# ============================================================================
# This template provides a structured framework for comprehensive gene 
# expression analysis from preprocessing through clinical validation
# ============================================================================

# Load required libraries
```{r}
library(DESeq2)
library(pheatmap)
library(ggplot2)
library(cluster)
library(survival)
library(survminer)
#library(clusterProfiler)
#library(org.Hs.eg.db)
library(dplyr)
library(tibble)
```


set.seed(123)

# ============================================================================
# STEP 1: DATA LOADING AND INITIAL SETUP
# ============================================================================

# TODO: Load your data files
# - count_matrix: raw counts (genes x samples)
# - clinical_data: patient clinical information
# - mutation_data: mutation status for each patient
```{r}
#Load the data (from lab 7)
RNAseq_KIRC <- read.csv("RNAseq_KIRC.csv")
data_clinical_patient <- read.delim("data_clinical_patient.txt", header = TRUE, sep = "\t", skip = 4)
data_mutations <- read.delim("data_mutations.txt", header = TRUE, sep = "\t", stringsAsFactors = FALSE)
```

```{r}
# RNAseq_KIRC dataset
rna_patient_ids <- gsub("\\.", "-", substr(colnames(RNAseq_KIRC), 1, 12))
# Data_clinical_patient dataset
clinical_patient_ids <- unique(data_clinical_patient$PATIENT_ID)
# Data_mutation dataset
mutation_patient_ids <- unique(substr(data_mutations$Tumor_Sample_Barcode, 1,
12))
# Common patients
common_patients <- Reduce(intersect, list(rna_patient_ids,
clinical_patient_ids, mutation_patient_ids))

# Patients in all three datasets
common_patients <- Reduce(intersect, list(
  rna_patient_ids,
  clinical_patient_ids,
  mutation_patient_ids
))
cat("Number of patients in ALL datasets:", length(common_patients), "\n")

```

# TODO: Verify data dimensions and alignment
# - Check that sample IDs match across all datasets
# - Confirm no missing critical values
# - Document sample size and gene count - done above?
```{r}
#colnames(data_clinical_patient)
#colnames(data_mutations)
```

```{r}
# Check for missing values
# RNA-seq:
rnaseq_missing <- sum(is.na(RNAseq_KIRC))
cat("Missing values in RNA-seq count matrix:", rnaseq_missing, "\n")

# Clinical: Check key columns
key_clinical_cols <- c("PATIENT_ID", "AGE", "SEX", "OS_STATUS", "OS_MONTHS", "DSS_STATUS", "DSS_MONTHS", "DFS_STATUS", "DFS_MONTHS", "PFS_STATUS", "PFS_MONTHS", "PATH_T_STAGE", "PATH_N_STAGE", "PATH_M_STAGE", "AJCC_PATHOLOGIC_TUMOR_STAGE")
existing_cols <- key_clinical_cols[key_clinical_cols %in% colnames(data_clinical_patient)]

if(length(existing_cols) > 0) {
  for(col in existing_cols) {
    missing_count <- sum(is.na(data_clinical_patient[[col]]) | data_clinical_patient[[col]] == "")
    cat("Missing/empty values in", col, ":", missing_count, "\n")
  }
}

# Mutations: Check key columns
cat("\nMissing values in Tumor_Sample_Barcode:", sum(is.na(data_mutations$Tumor_Sample_Barcode)), "\n")
cat("Missing/empty values in Hugo_Symbol:", sum(is.na(data_mutations$Hugo_Symbol) | data_mutations$Hugo_Symbol == ""), "\n")
cat("Missing/empty values in Variant_Classificatoin:", sum(is.na(data_mutations$Variant_Classification) | data_mutations$Variant_Classificationl == ""), "\n")
cat("Missing/empty values in Consequence:", sum(is.na(data_mutations$Consequence) | data_mutations$Consequence == ""), "\n")
cat("Missing/epmty values in Impact:", sum(is.na(data_mutations$IMPACT) | data_mutations$IMPACT == ""), "\n\n")
```


# ============================================================================
# STEP 2: PREPROCESSING
# ============================================================================

## 2.1: Normalization using DESeq2
# GOAL: Account for sequencing depth and composition bias

# TODO: Create DESeq2 object from raw counts
# TODO: Estimate size factors
# TODO: Extract normalized counts
# TODO: Quality check: plot size factors, check for outliers
```{r}
# Create DESeq2 object from raw counts
# Prepare count matrix (genes as rows, samples as columns)
count_matrix <- as.matrix(RNAseq_KIRC[, -1])  # Remove gene name column
rownames(count_matrix) <- RNAseq_KIRC[, 1]    # Set gene names as row names

# Create a simple sample metadata data frame
# For normalization, we just need a basic colData with sample names
coldata <- data.frame(
  sample = colnames(count_matrix),
  condition = rep("tumor", ncol(count_matrix))  # Placeholder condition
)
rownames(coldata) <- coldata$sample

cat("Creating DESeq2 dataset object...\n")
cat("Count matrix dimensions:", dim(count_matrix), "\n")

# Create DESeq2 dataset object
dds <- DESeqDataSetFromMatrix(
  countData = count_matrix,
  colData = coldata,
  design = ~ 1  # No DE, normalization only
)
cat("DESeq2 object created successfully\n\n")

# Estimate size factors
cat("Estimating size factors...\n")
dds <- estimateSizeFactors(dds)

# Get size factors
size_factors <- sizeFactors(dds)

cat("Size factors estimated for", length(size_factors), "samples\n")
cat("Size factor summary:\n")
print(summary(size_factors))
cat("\n")

# Extract normalized counts
cat("Extracting normalized counts...\n")
normalized_counts <- counts(dds, normalized = TRUE)

cat("Normalized count matrix dimensions:", dim(normalized_counts), "\n")
cat("Example normalized counts (first 5 genes, first 3 samples):\n")
print(normalized_counts[1:5, 1:3])
cat("\n")

sf <- sizeFactors(dds)
```

## 2.2: Log-transformation
# GOAL: Stabilize variance and make data more normally distributed

# TODO: Apply log2 transformation with pseudocount (log2(x + 1))
# TODO: Quality check: compare distributions before/after log transform
# TODO: Visualize: density plots or histograms

```{r}
# Apply log2 transformation with pseudocount (log2(x + 1))
# Log2 transform with pseudocount to avoid log(0)
log2_counts <- log2(normalized_counts + 1)

cat("Log2 transformed count matrix dimensions:", dim(log2_counts), "\n")
cat("Example log2 counts (first 5 genes, first 3 samples):\n")
print(log2_counts[1:5, 1:3])
cat("\n")

# Quality check: compare distributions before/after log transform
# Calculate summary statistics for a random sample
set.seed(123)
sample_gene <- sample(1:nrow(normalized_counts), 1)

cat("Example gene:", rownames(normalized_counts)[sample_gene], "\n")
cat("\nBefore log transformation (normalized counts):\n")
print(summary(normalized_counts[sample_gene, ]))
cat("\nAfter log transformation:\n")
print(summary(log2_counts[sample_gene, ]))
cat("\n")
```

## 2.3: Z-score transformation
# GOAL: Standardize gene expression across samples

# TODO: Calculate z-scores per gene (across samples)
# TODO: Verify mean ≈ 0 and sd ≈ 1 for each gene
# TODO: Quality check: heatmap of sample correlations
```{r}
## 2.3: Z-score transformation
# GOAL: Standardize gene expression across samples

#Calculate z-scores per gene (across samples)
# Calculate z-scores: (x - mean) / sd for each gene across all samples
# Using t() to transpose because scale() works on columns, but we want to scale rows (genes)
z_scores <- t(scale(t(log2_counts)))

cat("Z-score matrix dimensions:", dim(z_scores), "\n")
cat("Example z-scores (first 5 genes, first 3 samples):\n")
print(z_scores[1:5, 1:3])
cat("\n")

# Verify mean ≈ 0 and sd ≈ 1 for each gene
# Calculate row means and row standard deviations of the z-score matrix
row_means <- rowMeans(z_scores)
row_sds   <- apply(z_scores, 1, sd)

# Print summaries
cat("Summary of row means (should be ~0):\n")
print(summary(row_means))

cat("\nSummary of row standard deviations (should be ~1):\n")
print(summary(row_sds))

# Optionally check the first few explicitly
cat("\nFirst 5 row means:\n")
print(row_means[1:5])

cat("\nFirst 5 row SDs:\n")
print(row_sds[1:5])
```


# CHECKPOINT: Save preprocessed expression matrix for all analyses

# ============================================================================
# INVESTIGATION 1: Global Expression-Based Clustering
# RQ 2.1: Do patients cluster into distinct phenotype subtypes?
# ============================================================================

## GOAL: Identify natural patient groupings based on global gene expression

## Step 1.1: Distance calculation
# TODO: Transpose matrix (samples as rows)
# TODO: Calculate distance matrix (Euclidean or correlation-based)
# TODO: Document distance metric choice and rationale

## Step 1.2: Hierarchical clustering
# TODO: Perform hierarchical clustering (method: ward.D2, complete, or average)
# TODO: Create dendrogram visualization
# TODO: Try multiple linkage methods and compare

## Step 1.3: Determine optimal number of clusters
# TODO: Calculate silhouette scores for k = 2 to 10
# TODO: Plot silhouette scores vs k
# TODO: Consider gap statistic as alternative
# TODO: Examine dendrogram for natural breaks
# TODO: DECISION: Choose optimal k based on metrics

## Step 1.4: Cut tree and assign cluster labels
# TODO: Cut dendrogram at chosen k
# TODO: Create cluster assignment vector
# TODO: Document cluster sizes

## Step 1.5: Dimensionality reduction visualization
# TODO: Perform PCA on expression data
# TODO: Plot PC1 vs PC2 colored by cluster
# TODO: Calculate variance explained by top PCs
# TODO: Alternative: try t-SNE or UMAP

## Step 1.6: Cluster validation
# TODO: Calculate silhouette width for each sample
# TODO: Identify poorly clustered samples
# TODO: Check cluster stability (bootstrap or subsample)

## CONCLUSION FOR RQ 2.1:
# TODO: Report number of distinct clusters identified
# TODO: Describe separation quality (silhouette scores, visual separation)
# TODO: Note any outlier samples or unclear assignments

# ============================================================================
# INVESTIGATION 2: High-Variance Gene Clustering
# RQ 2.2: How does focusing on variable genes influence clustering?
# ============================================================================

## GOAL: Determine if highly variable genes drive clustering patterns

## Step 2.1: Identify top variable genes
# TODO: Calculate variance for each gene (use log-transformed data)
# TODO: Rank genes by variance
# TODO: Select top 500 most variable genes
# TODO: Create filtered expression matrix (500 genes x all samples)

## Step 2.2: Visualize variable genes
# TODO: Plot variance distribution across all genes
# TODO: Highlight top 500 selected genes
# TODO: Optional: heatmap of top variable genes

## Step 2.3: Re-cluster with variable genes only
# TODO: Calculate new distance matrix on 500-gene subset
# TODO: Perform hierarchical clustering
# TODO: Determine optimal k (may differ from Investigation 1)
# TODO: Cut tree and assign new cluster labels

## Step 2.4: Compare clustering results
# TODO: Create confusion matrix: Investigation 1 clusters vs Investigation 2 clusters
# TODO: Calculate adjusted Rand index (ARI) to measure agreement
# TODO: Identify samples that switch clusters
# TODO: PCA visualization with both cluster assignments

## Step 2.5: Biological interpretation
# TODO: Are variable gene clusters more/less distinct?
# TODO: Does focusing on variable genes change cluster structure?
# TODO: Which clustering is more biologically coherent?

## CONCLUSION FOR RQ 2.2:
# TODO: Report which genes show highest variability
# TODO: Describe impact on clustering (stronger/weaker separation)
# TODO: Recommend which gene set to use for downstream analyses
# TODO: DECISION: Choose clustering result for Investigations 3-7

# ============================================================================
# INVESTIGATION 3: Differential Expression Analysis
# RQ 2.3: Which genes are differentially expressed between clusters?
# ============================================================================

## GOAL: Identify marker genes that distinguish patient clusters

## Step 3.1: Prepare data for DE analysis
# TODO: Use original raw counts (not normalized/transformed)
# TODO: Add cluster assignments to sample metadata
# TODO: Verify cluster labels match sample order

## Step 3.2: Set up DESeq2 for multi-group comparison
# TODO: Create DESeq2 object with cluster as design variable
# TODO: Run DESeq2 normalization and dispersion estimation
# TODO: Fit negative binomial model

## Step 3.3: Pairwise DE comparisons
# TODO: Extract results for all pairwise cluster comparisons
#       Example: If 3 clusters, test: 1vs2, 1vs3, 2vs3
# TODO: For each comparison:
#       - Extract results table
#       - Apply significance thresholds (padj < 0.05, |log2FC| > 1)
#       - Count number of DE genes
#       - Separate upregulated vs downregulated

## Step 3.4: Identify cluster-specific markers
# TODO: Find genes uniquely upregulated in each cluster
# TODO: Create Venn diagram of DE genes across comparisons
# TODO: List top 10-20 marker genes per cluster (by log2FC or padj)

## Step 3.5: Visualizations
# TODO: Volcano plots for each pairwise comparison
# TODO: MA plots to check for systematic bias
# TODO: Heatmap of top DE genes across all samples
# TODO: Boxplots for selected marker genes

## Step 3.6: Functional annotation of DE genes
# TODO: For each cluster's markers, note gene functions
# TODO: Are markers enriched for specific biological processes?
# TODO: Do markers make biological sense for phenotype differences?

## CONCLUSION FOR RQ 2.3:
# TODO: Report total number of DE genes between clusters
# TODO: Highlight strongest marker genes for each cluster
# TODO: Describe biological themes (immune, metabolic, proliferation, etc.)
# TODO: Save DE results tables for pathway analysis

# ============================================================================
# INVESTIGATION 4: Pathway Enrichment Analysis
# RQ 2.4: Which biological pathways are enriched in DE genes?
# ============================================================================

## GOAL: Identify functional pathways that differentiate clusters

## Step 4.1: Define gene sets for enrichment
# TODO: Filter DE genes by p-value threshold (use average p-value as cutoff)
# TODO: For each cluster comparison, create list of significant genes
# TODO: Consider separate analyses for up- vs down-regulated genes

## Step 4.2: Gene ID conversion
# TODO: Convert gene symbols to Entrez IDs (required for clusterProfiler)
# TODO: Handle genes that fail to convert
# TODO: Document conversion success rate

## Step 4.3: GO enrichment analysis
# TODO: Run enrichGO for Biological Process (BP)
# TODO: Run enrichGO for Molecular Function (MF)
# TODO: Run enrichGO for Cellular Component (CC)
# TODO: Set significance threshold (padj < 0.05)
# TODO: Specify background gene set (all expressed genes)

## Step 4.4: KEGG pathway enrichment
# TODO: Run enrichKEGG analysis
# TODO: Set organism code (e.g., "hsa" for human)
# TODO: Apply multiple testing correction

## Step 4.5: Alternative pathway databases (optional)
# TODO: Consider Reactome, MSigDB, WikiPathways
# TODO: Disease-specific databases if relevant

## Step 4.6: Visualizations
# TODO: Dotplot of top enriched pathways (by p-value and gene ratio)
# TODO: Barplot of enrichment scores
# TODO: Network plot showing pathway relationships
# TODO: Enrichment map connecting related pathways

## Step 4.7: Cluster-specific pathway profiles
# TODO: Compare enriched pathways across all clusters
# TODO: Which pathways are unique to each cluster?
# TODO: Which pathways are shared?
# TODO: Create summary table of key pathways per cluster

## Step 4.8: Biological interpretation
# TODO: Do pathways align with known disease subtypes?
# TODO: Are there actionable therapeutic targets?
# TODO: Do pathways explain clinical differences?

## CONCLUSION FOR RQ 2.4:
# TODO: List top 5-10 pathways for each cluster
# TODO: Describe biological themes (e.g., immune activation, cell cycle)
# TODO: Highlight novel or unexpected pathway enrichments
# TODO: Relate pathway findings back to DE genes from Investigation 3

# ============================================================================
# INVESTIGATION 5: Clinical Outcome Analysis
# RQ 2.5: Do expression-based clusters differ in patient outcomes?
# ============================================================================

## GOAL: Determine if molecular clusters predict clinical outcomes

## Step 5.1: Prepare survival data
# TODO: Extract survival time and event status from clinical data
# TODO: Verify data format (time = numeric, status = 0/1 or 1/2)
# TODO: Handle missing or censored data appropriately
# TODO: Add cluster assignments to survival data

## Step 5.2: Descriptive statistics
# TODO: Calculate median survival time per cluster
# TODO: Count number of events (deaths/relapses) per cluster
# TODO: Tabulate follow-up time distribution

## Step 5.3: Kaplan-Meier survival analysis
# TODO: Fit survival curves for each cluster
# TODO: Plot Kaplan-Meier curves with confidence intervals
# TODO: Add risk table showing n at risk over time
# TODO: Customize plot aesthetics (colors, labels)

## Step 5.4: Statistical testing
# TODO: Perform log-rank test across all clusters
# TODO: Report chi-square statistic and p-value
# TODO: If >2 clusters, do pairwise log-rank tests with correction
# TODO: Interpret significance of survival differences

## Step 5.5: Cox proportional hazards model
# TODO: Fit Cox model with cluster as predictor
# TODO: Calculate hazard ratios (HR) for each cluster
# TODO: Test proportional hazards assumption
# TODO: Report HRs with 95% confidence intervals

## Step 5.6: Multivariable survival analysis
# TODO: Add clinical covariates (age, stage, sex) to Cox model
# TODO: Determine if clusters remain prognostic after adjustment
# TODO: Check for confounding or effect modification
# TODO: Report adjusted HRs

## Step 5.7: Survival prediction performance
# TODO: Calculate concordance index (C-index) for cluster-based model
# TODO: Compare to clinical-only model
# TODO: Assess added prognostic value of molecular clusters

## CONCLUSION FOR RQ 2.5:
# TODO: Report whether clusters have significantly different outcomes
# TODO: Identify high-risk vs low-risk clusters
# TODO: Quantify magnitude of difference (median survival, HR)
# TODO: State whether molecular clusters add prognostic value beyond clinical factors

# ============================================================================
# INVESTIGATION 6: Clinical Variable Associations
# RQ 2.6: Do clusters differ in clinical characteristics?
# ============================================================================

## GOAL: Characterize clinical profiles of molecular clusters

## Step 6.1: Prepare clinical data
# TODO: Merge cluster assignments with clinical data
# TODO: Identify all available clinical variables
# TODO: Classify variables as continuous vs categorical
# TODO: Handle missing data (document and decide on exclusion/imputation)

## Step 6.2: Continuous variables analysis
# TODO: For each continuous variable (age, BMI, lab values):
#       - Test normality within each cluster (Shapiro-Wilk)
#       - Choose appropriate test: ANOVA (normal) or Kruskal-Wallis (non-normal)
#       - Calculate test statistic and p-value
#       - Perform post-hoc pairwise tests if significant
# TODO: Create summary table with mean/median per cluster

## Step 6.3: Visualize continuous variables
# TODO: Boxplots for each variable by cluster
# TODO: Violin plots showing distributions
# TODO: Add statistical annotations (p-values)

## Step 6.4: Categorical variables analysis
# TODO: For each categorical variable (sex, stage, race, etc.):
#       - Create contingency table (cluster x category)
#       - Perform chi-square or Fisher's exact test
#       - Calculate Cramér's V for effect size
#       - Report observed vs expected frequencies
# TODO: Create summary table with proportions per cluster

## Step 6.5: Visualize categorical variables
# TODO: Stacked or grouped bar plots showing proportions
# TODO: Mosaic plots for complex cross-tabulations
# TODO: Highlight significant associations

## Step 6.6: Disease stage/grade analysis
# TODO: Test if clusters associate with disease severity
# TODO: Are certain clusters enriched for advanced stage?
# TODO: Calculate odds ratios for stage by cluster

## Step 6.7: Multiple testing correction
# TODO: Adjust p-values for multiple comparisons (Bonferroni or FDR)
# TODO: Report both raw and adjusted p-values
# TODO: Interpret significance after correction

## Step 6.8: Multivariate analysis
# TODO: Use multinomial logistic regression (cluster as outcome)
# TODO: Include multiple clinical predictors simultaneously
# TODO: Identify independent clinical predictors of cluster membership

## Step 6.9: Clinical cluster profiling
# TODO: Create comprehensive profile for each cluster
# TODO: Example: "Cluster 1: younger, more female, early stage"
# TODO: Identify clinically distinct subtypes

## CONCLUSION FOR RQ 2.6:
# TODO: Summarize which clinical variables differ significantly
# TODO: Describe clinical profile of each cluster
# TODO: Assess whether clusters represent clinically meaningful subtypes
# TODO: Discuss implications for patient stratification

# ============================================================================
# INVESTIGATION 7: Mutation Enrichment Analysis
# RQ 2.7: Are specific mutations enriched in particular clusters?
# ============================================================================

## GOAL: Link genetic alterations to expression-based subtypes

## Step 7.1: Prepare mutation data
# TODO: Ensure mutation data matches sample IDs in expression data
# TODO: Verify mutation format (binary, count, or VAF)
# TODO: Document mutation prevalence (% samples affected per mutation)
# TODO: Merge cluster assignments with mutation data

## Step 7.2: Individual mutation testing
# TODO: For each mutation:
#       - Create 2x2 or 2xK contingency table (mutation x cluster)
#       - Perform Fisher's exact test (if small counts) or chi-square
#       - Calculate odds ratios for mutation in each cluster
#       - Record p-value and effect size
# TODO: Create results table for all mutations tested

## Step 7.3: Multiple testing correction
# TODO: Adjust p-values across all mutation tests (FDR/Bonferroni)
# TODO: Identify mutations with significant enrichment after correction
# TODO: Rank mutations by significance

## Step 7.4: Visualize mutation enrichment
# TODO: Heatmap showing mutation frequency per cluster
# TODO: Bar plots for significantly enriched mutations
# TODO: Stacked bar plots showing proportion mutated per cluster
# TODO: Consider oncoplot-style visualization

## Step 7.5: Cluster-specific mutation profiles
# TODO: For each cluster, list enriched mutations
# TODO: Calculate enrichment fold-change vs other clusters
# TODO: Identify mutually exclusive or co-occurring mutations

## Step 7.6: Mutation burden analysis
# TODO: Calculate total mutation count per sample
# TODO: Test if clusters differ in overall mutation burden
# TODO: Use ANOVA or Kruskal-Wallis test
# TODO: Visualize with boxplots

## Step 7.7: Pathway-level mutation analysis
# TODO: Group mutations by affected pathway (e.g., TP53, RAS, PI3K)
# TODO: Test pathway-level enrichment in clusters
# TODO: Does cluster with pathway X mutations have pathway X expression changes?

## Step 7.8: Mutation-expression correlation
# TODO: For enriched mutations, examine expression of mutated gene
# TODO: Do mutations correlate with gene expression changes?
# TODO: Are there compensatory expression changes?

## Step 7.9: Integration with DE genes
# TODO: Cross-reference with Investigation 3 results
# TODO: Do clusters with specific mutations show corresponding expression signatures?
# TODO: Example: Are TP53-mutated samples in a specific cluster with p53 pathway dysregulation?

## Step 7.10: Biological interpretation
# TODO: Do mutation patterns explain molecular subtypes?
# TODO: Are there known oncogenic driver mutations enriched in clusters?
# TODO: Do findings suggest distinct disease etiologies?

## CONCLUSION FOR RQ 2.7:
# TODO: List mutations significantly enriched in each cluster
# TODO: Report magnitude of enrichment (OR, fold-change)
# TODO: Describe mutation-based characterization of each cluster
# TODO: Discuss whether mutations drive observed expression differences
# TODO: Identify potential therapeutic vulnerabilities based on mutations

# ============================================================================
# STEP 3: INTEGRATED SYNTHESIS AND FINAL CONCLUSIONS
# ============================================================================

## Step 3.1: Cross-investigation integration
# TODO: Create comprehensive table summarizing all clusters:
#       - Size, marker genes, pathways, outcome, clinical features, mutations
# TODO: Develop unified narrative for each cluster
# TODO: Name clusters based on characteristics (e.g., "Immune-hot", "Proliferative")

## Step 3.2: Validate findings
# TODO: Check consistency across investigations
# TODO: Do DE genes align with enriched pathways?
# TODO: Do mutations explain expression patterns?
# TODO: Are clinical features consistent with molecular profiles?

## Step 3.3: Biological coherence
# TODO: Assess whether clusters represent biologically distinct subtypes
# TODO: Compare to known disease classifications or published subtypes
# TODO: Discuss novelty or confirmation of findings

## Step 3.4: Clinical relevance
# TODO: Identify actionable clusters (targetable pathways/mutations)
# TODO: Recommend cluster-specific treatment strategies
# TODO: Suggest prognostic biomarkers based on cluster membership

## Step 3.5: Limitations and caveats
# TODO: Document sample size limitations
# TODO: Note any batch effects or technical confounders
# TODO: Acknowledge multiple testing burden
# TODO: Discuss generalizability

## Step 3.6: Future directions
# TODO: Suggest validation in independent cohort
# TODO: Propose functional experiments to test hypotheses
# TODO: Recommend additional molecular data types (methylation, proteomics)

## FINAL DELIVERABLES:
# TODO: Summary figure showing cluster characteristics
# TODO: Supplementary tables with all statistical results
# TODO: Write methods section documenting all analyses
# TODO: Prepare results section with key findings per RQ

# ============================================================================
# END OF TEMPLATE
# ============================================================================


